BridgeMD
New treatment option for Lung Cancer (NSCLC)
Official title Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
ClinicalTrials.gov ID: NCT06634979
What this study is testing
- What it's testing
- The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
- Age 18-80 years at time of signing informed consent (including threshold);
- ECOG score 0 or 1;
- No previous surgery for lung cancer;
- Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
You likely can't join if
- T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm;
- Inability to perform complete surgical resection;
- cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
- Previous surgery for lung cancer;
- Patients who have received radiotherapy or chemotherapy for non-primary treatment.
See the full eligibility criteria
- Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
- Age 18-80 years at time of signing informed consent (including threshold);
- ECOG score 0 or 1;
- No previous surgery for lung cancer;
- Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
- Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
- The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
- Patients with clinical stage T1N0M0 surgically resectable;
- Primary treatment without radiotherapy or chemotherapy.
- T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm;
- Inability to perform complete surgical resection;
- cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
- Previous surgery for lung cancer;
- Patients who have received radiotherapy or chemotherapy for non-primary treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.